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Abstract
Background: Wasting is known as a prominent feature of tuberculosis (TB). To monitor the disease state, markers of
metabolism and inflammation are potentially useful. We thus analyzed two major adipokines, adiponectin and leptin, and
two other metabolic markers, fetuin-A and retinol-binding protein 4 (RBP4).
Methods: The plasma levels of these markers were measured using enzyme-linked immunosorbent assays in 84 apparently
healthy individuals (=no-symptom group) and 46 patients with active pulmonary TB around the time of treatment,
including at the midpoint evaluation (=active-disease group) and compared them with body mass index (BMI), C-reactive
protein (CRP), chest radiographs and TB-antigen specific response by interferon-c release assay (IGRA).
Results: In the no-symptom group, adiponectin and leptin showed negative and positive correlation with BMI respectively.
In the active-disease group, at the time of diagnosis, leptin, fetuin-A and RBP4 levels were lower than in the no-symptom
group [adjusted means 2.01 versus 4.50 ng/ml, P,0.0001; 185.58 versus 252.27 mg/ml, P,0.0001; 23.88 versus 43.79 mg/ml,
P,0.0001, respectively]. High adiponectin and low leptin levels were associated with large infiltrates on chest radiographs
even after adjustment for BMI and other covariates (P=0.0033 and P=0.0020). During treatment, adiponectin levels
increased further and then decreased. Leptin levels remained low. Initial low levels of fetuin-A and RBP4 almost returned to
the normal reference range in concert with reduced CRP.
Conclusions: Our data and recent literature suggest that low fat store and underlying inflammation may regulate these
metabolic markers in TB in a different way. Decreased leptin, increased adiponectin, or this ratio may be a promising marker
for severity of the disease independent of BMI. We should further investigate pathological roles of the balance between
these adipokines.
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Introduction
Tuberculosis (TB) is a major infectious cause of death around
the world, with most of the 1.5 million deaths per year attributable
to the disease occurring in developing countries. Negative energy
balance in chronic inflammation has been recognized as
a prominent feature of TB and one of the major obstacles to
manage the patients [1,2]. Recent emergence of drug resistant TB
is assumed to be driven by poorly implemented drug regimens, but
malnutrition as well as HIV co-infection might worsen the
condition: Inflammatory responses evoked by infection increase
the demand for anabolic energy, leading to a synergistic vicious
circle and further deterioration of the clinical condition [3].
It is generally believed that undernourishment diminishes
protective immunity against Mycobacterium tuberculosis. [4]. A series
of animal experiments, particularly aerosol-infected guinea pig
models have demonstrated that chronic protein-energy malnutri-
tion reduces secretion of T-helper 1 (Th1) cytokines [5]. It is
rapidly reversed with alimentary supplement, indicating a pivotal
role of nutrition, although it remains unclear what the optimal
nutritional interventions are for improving the human disease in
an effective manner [4].
On the other hand, in many countries today, rapid in-
dustrialization and urbanization are accompanied by changing
patterns of diet and physical activity and this results in over-
nutrition [6]. Consequently, a combination of these two unfavor-
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with undernutrition and a rapid increase in obesity and diabetes
are a serious double burden to public health and clinical medicine
in resource limited settings [7].
Mainly in studies carried out in industrialized countries, fat-cell-
derived hormones/cytokines designated as adipokines and rele-
vant mediators have been investigated extensively and proposed as
markers of obesity and diabetes [8]. Of these adipokines,
adiponectin is a unique insulin sensitizer with atheroprotective
role [9,10]. Plasma levels of adiponectin are inversely correlated
with body weight and visceral fat mass [11,12]. Leptin is another
major adipokine in proportion to fat stores [13,14] and one of the
key mediators of energy metabolism [2] Even mild weight loss
induced by dietary restriction is known to reduce leptin levels [11].
These markers supposedly shift towards the opposite in lean
patients with wasting diseases. However, the significance of these
metabolic markers in chronic infectious diseases like TB has not
been fully understood [2].
We have recently conducted a proteomic research and
demonstrated that plasma levels of fetuin-A and retinol-binding
protein 4 (RBP4), also closely linked to the metabolic and
inflammatory state, were significantly lower in patients with active
pulmonary TB than in control subjects [15]. Fetuin-A, also known
as a2-Heremans-Schmid glycoprotein, is an abundant plasma
component of hepatic origin [16] and a negative regulator of
insulin signaling [17,18]. Elevation of plasma fetuin-A is strongly
associated with atherogenic lipid profile as well as fatty liver in
obese patients [18]. Lipid components in the liver presumably
upregulate fetuin-A expression, which may in turn repress
adiponectin and impair adipocyte function [19,20]. Fetuin-A is
also downregulated in acute inflammation as a negative acute-
phase protein [21]. RBP4, synthesized in the liver and adipose
tissue, has recently been identified as another adipokine involved
in the development of insulin resistance [22]. In humans, similar to
leptin, circulating RBP4 levels are high in obesity and decreased
after calorie-restriction induced weight loss [11,23]. RBP4 is also
known as a specific transporter protein for retinol (vitamin A) and
can be used to assess the short-term fluctuation of nutritional states
as a rapid turnover protein [24].
Alteration of the circulating levels of these markers should be
investigated in TB, since they are expected to provide a basis of
a critical link among nutritional status, metabolism and immunity
of the disease, and hopefully to consider efficient nutritional
interventions. In the present study, we thus measured circulating
adiponectin and leptin in addition to fetuin-A and RBP4 levels in
patients with active pulmonary TB versus apparently healthy
individuals and compared the levels with body mass index (BMI),
a simple estimate of adiposity [25] and C-reactive protein (CRP),
Table 1. Characteristics of study population.
no-symptom group (N=84) active-disease group (N=46) P values
Male/Female (n) 41/43 42/4 ,0.0001
Age (year)* 40.0 (28.1–48.6) 47.2 (34.7–55.0) 0.0064
BMI (kg/m
2)* 21.8 (20.0–23.7) 18.3 (17.1–19.5) ,0.0001
BCG history (yes/no/unknown) 33/28/23 10/3/33 ,0.0001
positive/negative results of IGRA (n) 55/29 41/4** 0.0015
*Median and 25-to-75 percentiles in parenthesis are shown.
**One indeterminate case is not shown here.
doi:10.1371/journal.pone.0038703.t001
Table 2. Correlation of tested marker levels with BMI, CRP and IGRA values in each of the no-symptom and active-disease groups.
no-symptom group (N=84) active-disease group (N=46)
Pearson’s r (P values)
a Pearson’s r (P values)
a
Variable
by BMI
(kg/m
2)
by CRP
(mg/ml)
by IFN-c
(IU/ml)
b
by BMI
(kg/m
2)
by CRP
(mg/ml)
by IFN-c
(IU/ml)
b
Adiponectin (mg/ml) 20.4530 20.2892 20.2254 20.4421 0.1477 20.1092
(,0.0001)* (0.0076) (0.0393) (0.0021) (0.3274) (0.4700)
Leptin (ng/ml) 0.4518 0.1694 0.1179 0.2771 20.0918 0.3568
(,0.0001)* (0.1234) (0.2855) (0.0623) (0.5442) (0.0149)
Leptin/adiponectin ratio 0.5820 0.2793 0.2067 0.4901 20.1633 0.2804
(,0.0001)* (0.0101) (0.0592) (0.0005)* (0.2783) (0.0591)
Fetuin-A (mg/ml) 0.0309 0.0415 0.0322 0.1243 20.1833 0.2402
(0.7805) (0.7079) (0.7714) (0.4105) (0.2226) (0.1078)
RBP4 (mg/ml) 0.1605 20.0213 0.0716 0.1535 20.3018 20.0916
(0.1447) (0.8475) (0.5173) (0.3085) (0.0415) (0.5448)
aPearson’s correlation coefficients with P values were calculated. Plasma concentrations were analyzed after logarithmic transformation.
bTB-antigen stimulated IFN-c response
*Statistically significant when the significance level is set as P,0.002 based on the Bonferrroni correction.
doi:10.1371/journal.pone.0038703.t002
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characterized their relationship with disease severity and altera-
tions during the course of treatment.
Methods
Study design
We randomly selected and used plasma samples and de-
mographic information in 46 patients with active pulmonary TB
(=active-disease group) without treatment history as a biomarker
sub-study of a large cohort study [27]. All patients entered the
study from July 2007 to March 2009. Diagnosis of active
pulmonary TB was made clinically and radiologically and
confirmed bacteriologically in Hanoi Lung Hospital. A sputum
smear test showed positive results in all of the patients in the active
disease group and all of them completed anti-TB treatment
following the national standard regimen, 2 months of streptomy-
cin, isoniazid, rifampicin, and pyrazinamide followed by 6 months
of isoniazid and ethambutol (2SHRZ/6HE).
Chest radiographs were taken at the time of diagnosis and
interpreted by two readers independently in a blind manner. The
presence of cavitary lesions and the number of lung zones (zero to
six corresponding to the upper, middle, and lower fields on the
right and left sides of the lung) affected by infiltrates were recorded
[28]. HIV status was examined before starting anti-TB treatment.
The proportion of HIV co-infection is less than 10% in this study
area and those with HIV positive were excluded from the drawing
up of this sub-study.
As a reference, we also measured plasma samples derived from
84 apparently healthy men and women who may have chances of
direct or indirect contacts with TB patients as health care staff
(=no-symptom group). All participants were tested for TB-antigen
specific interferon-c response by the commercially available
enzyme-linked immunosorbent assay (ELISA)-based interferon-c
release assay (IGRA), QuantiFERON-TB Gold In-Tube
TM
(Cellestis, Victoria, Australia). In the no-symptom group, IGRA-
positive individuals suspected of latent TB infection were
recommended to take chest radiography and to confirm there
were no active pulmonary lesions. Subsequently a chance of
receiving isoniazid prophylactic therapy was given. The protocol
was approved by ethical committees of the Ministry of Health,
Viet Nam and National Center for Global Health and Medicine,
Japan respectively and written informed consent was obtained
from each participant.
Table 3. BMI, CRP and tested marker levels in IGRA-positive and -negative subgroups in the no-symptom group.
IGRA-negative (N=29) IGRA-positive (N=55)
marker adjusted mean
a (95%CI) adjusted mean
a (95%CI)
P values
(ANCOVA)
BMI (kg/m
2) 21.52 (20.58–22.46) 21.48 (20.74–22.22) 0.9392
CRP (mg/ml) 1.12 (0.60–2.08) 1.30 (0.80–2.12) 0.6663
Adiponectin (mg/ml) 7.19 (5.67–9.11) 6.39 (5.30–7.70 ) 0.3792
Leptin (ng/ml) 4.50 (3.34–6.05) 4.38 (3.47–5.54) 0.8783
Leptin/adiponectin ratio 0.63 (0.40–0.97) 0.69 (0.49–0.97) 0.7080
Fetuin-A (mg/ml) 234.22 (212.40–258.29) 263.88 (244.26–285.06) 0.0333
RBP4 (mg/ml) 39.64 (32.28–48.69) 42.88 (36.45–50.43) 0.4997
aEstimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender and age as covariates. The data shown are
transformed back to the original unit.
No P values were statistically significant when the significance level is set as P,0.007 based on the Bonferrroni correction.
doi:10.1371/journal.pone.0038703.t003
Table 4. BMI, CRP and tested marker levels in the no-symptom and active-disease groups after adjustment for gender and age.
no-symptom group (N=84) active-disease group (N=46)
marker
adjusted
mean
a (95%CI)
adjusted
mean
a (95%CI)
P values
(ANCOVA)
BMI (kg/m
2) 21.68 (21.06–22.30) 17.65 (16.66–18.65) ,0.0001*
CRP (mg/ml) 1.22 (0.86–1.74) 36.88 (20.94–64.94) ,0.0001*
Adiponectin (mg/ml) 6.82 (5.73–8.12) 9.29 (7.02–12.30) 0.0136
Leptin (ng/ml) 4.50 (3.78–5.35) 2.01 (1.52–2.66) ,0.0001*
Leptin/adiponectin
ratio
0.66 (0.50–0.88) 0.22 (0.14–0.34) ,0.0001*
Fetuin-A (mg/ml) 252.27 (234.55–271.33) 185.58 (165.07–208.64) ,0.0001*
RBP4 (mg/ml) 43.79 (38.09–50.34) 23.88 (19.08–29.88) ,0.0001*
aEstimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender and age as covariates. The data shown are
transformed back to the original unit.
*Statistically significant when the significance level is set as P,0.007 based on the Bonferrroni correction.
doi:10.1371/journal.pone.0038703.t004
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inflammation
Immediately after making the diagnosis of active TB disease,
heparinized blood samples were drawn for IGRA before starting
anti-TB treatment (0 month) and the remaining plasma without
mixing any stimulants was reserved in a 280uC freezer until
measurement. Samples were collected twice again, after the initial
phase of treatment (2 months) and at the end of treatment (7
months) in the active disease group. This study was originally
intended to identify a variety of biomarkers associated with TB
phenotypes [15] and the participants were not obliged to keep
fasting. The blood was collected in the daytime between 8 am and
4 pm at the outpatient clinic to avoid interference in dosing
schedule of anti-TB drugs.
The AssayMax Human C-Reactive Protein ELISA kit was used
for detection of human c-reactive protein (CRP) in plasma
(Assaypro LLC. St. Charles, MO, USA). The minimum detectable
dose was less than 0.25 ng/ml. The QuantikineH Human Total
Adiponectin/Acrp30 Immunoassay kit was used to detect total
(low, middle and high molecular weight) human adiponectin in
plasma (R&D Systems, Inc.; Minneapolis, MN, USA). The mean
minimum detectable dose was 0.246 ng/ml. The QuantikineH
Human Leptin Immunoassay kit was used to detect human leptin
in plasma (R&D Systems, Inc.). The mean minimum detectable
dose was 7.8 pg/ml. The AHSG ELISA kit was used to detect
fetuin-A in plasma (BioVender Laboratory Medicine Inc.;
Modrice, Czech Republic). The detection limit was 0.35 ng/ml.
A competitive ELISA for quantitative determination of RBP4 in
human plasma was also applied (AdipoGen Inc.; Seoul, Korea)
and the detection limit was 1 ng/ml. All were performed
according to the manufacturer’s instructions. Differences in
measured concentrations between EDTA plasma samples as
reference and these heparin samples were within a range of
variation generally accepted in ELISA (coefficient of variance
,15%) (data not shown)
Statistical analysis
Plasma protein levels were served for subsequent statistical
analysis after logarithmic transformation of the measurements to
minimize distortion of the data distribution. Means of de-
mographic data between two groups were compared by analysis
of variance (ANOVA) after testing for equal variances and
Table 5. CRP and tested marker levels in the no-symptom and active-disease groups after adjustment for gender, age and BMI.
no-symptom group (N=84) active-disease group (N=46)
marker adjusted mean
a (95%CI) adjusted mean
a (95%CI)
P values
(ANCOVA)
CRP (mg/ml) 1.11 (0.77–1.60) 47.80 (25.36–90.09) ,0.0001*
Adiponectin (mg/ml) 7.80 (6.63–9.19) 6.39 (4.81–8.49) 0.1671
Leptin (ng/ml) 3.77 (3.26–4.37) 3.28 (2.54–4.24) 0.2790
Leptin/adiponectin ratio 0.48 (0.38–0.61) 0.51 (0.35–0.76) 0.7704
Fetuin-A (mg/ml) 248.04 (229.95–267.57) 194.46 (170.48–221.80) 0.0004*
RBP4 (mg/ml) 42.90 (37.08–49.63) 25.27 (19.62–32.55) 0.0001*
aEstimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender, age and BMI as covariates. The data shown are
transformed back to the original unit.
*Statistically significant when the significance level is set as P,0.008 based on the Bonferrroni correction.
doi:10.1371/journal.pone.0038703.t005
Table 6. BMI, CRP and tested marker levels in patients with small and large infiltrates on chest radiographs after adjustment for
gender and age.
small infiltrates
a (N=22) large infiltrates
a (N=23)
marker adjusted mean
b (95%CI) adjusted mean
b (95%CI) P values (ANCOVA)
BMI (kg/m
2) 18.73 (16.74–20.71) 18.11 (15.95–20.27) 0.3065
CRP (mg/ml) 26.14 (12.63–54.10) 35.92 (16.29–79.21) 0.1520
Adiponectin (mg/ml) 10.28 (5.38–19.66) 18.83 (9.31–38.11) 0.0033*
Leptin (ng/ml) 2.42 (1.64–3.57) 1.65 (1.08–2.52) 0.0020*
Leptin/adiponectin ratio 0.24 (0.11–0.52) 0.09 (0.04–0.21) 0.0002*
Fetuin-A (mg/ml) 201.97 (149.87–272.18) 184.68 (133.52–255.46) 0.3222
RBP4 (mg/ml) 36.14 (21.76–60.03) 31.56 (18.17–54.79) 0.3770
IFN-c (IU/ml)
c 11.04 (2.13–57.16) 5.80 (0.97–34.82) 0.2039
aSmall infiltrates=less than 3 of 6 zones in the lung affected, large infiltrates=3 or more than 3 of 6 zones affected
bEstimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender and age as covariates. The data shown are
transformed back to the original unit.
cTB-antigen stimulated IFN-c response
*Statistically significant when the significance level is set as P,0.006 based on the Bonferrroni correction.
doi:10.1371/journal.pone.0038703.t006
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squared test. Since it is well known that levels of adipokines such as
leptin are influenced by gender and age, measurements of protein
markers in any two groups were compared by analysis of
covariance (ANCOVA) to allow for the covariates. The relation-
ship between markers and other parameters were assessed by
Pearson’s correlation coefficients. Overall alterations of the
measurements at three time points were initially analyzed by
repeated-measures ANOVA and only when statistically significant,
post-hoc comparisons were proceeded to: Difference of values
between two time points was assessed by the paired-T test, under
normal approximation based on the central limit theorem. P
values,0.05 were considered to be statistically significant in
general. When the Bonferroni correction was applied, however,
a level of statistical significance was set as 0.05/n (n=the number
of comparisons). Statistical analysis was performed using Stata
version 11 (StataCorp, College Station, TX, USA).
Table 7. CRP and tested marker levels in patients with small and large infiltrates on chest radiographs after adjustment for gender,
age and BMI.
small infiltrates
a (N=22) large infiltrates
a (N=23)
marker adjusted mean
b (95%CI) adjusted mean
b (95%CI) P values (ANCOVA)
CRP (mg/ml) 26.59 (12.78–55.28) 35.50 (16.02–78.63) 0.1991
Adiponectin (mg/ml) 10.84 (6.01–19.53) 18.15 (9.57–34.40) 0.0061*
Leptin (ng/ml) 2.37 (1.63–3.47) 1.67 (1.11–2.52) 0.0040*
Leptin/adiponectin ratio 0.22 (0.11–0.44) 0.09 (0.04–0.20) 0.0002*
Fetuin-A (mg/ml) 200.77 (148.59–271.28) 185.46 (133.74–257.18) 0.3886
RBP4 (mg/ml) 35.69 (21.43–59.46) 31.83 (18.29–55.42) 0.4626
IFN-c (IU/ml)
c 11.41 (2.17–59.90) 5.68 (0.94–34.53) 0.1760
aSmall infiltrates=less than 3 of 6 zones in the lung affected, large infiltrates=3 or more than 3 of 6 zones affected
bEstimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender, age and BMI as covariates. The data shown are
transformed back to the original unit.
cTB-antigen stimulated IFN-c response
*Statistically significant when the significance level is set as P,0.007 based on the Bonferrroni correction.
doi:10.1371/journal.pone.0038703.t007
Figure 1. CRP and tested marker levels in patients with active TB before (0 month), during (2 months) and at the end (7 months) of
anti-TB treatment (N=46). Vertical bars with diamonds on the left side (M and F) indicate reference values, means 6 SEM of the values in men
(N=41) and women (N=43) of the no-symptom group. A horizontal bar indicates the grand mean of the values in each condition. * indicates P,0.05
by paired comparison between 0 month and 2 months. When significant, 2 months and 7 months were also compared.
doi:10.1371/journal.pone.0038703.g001
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Characteristics of study population
The no-symptom group consisted of 84 apparently healthy
individuals, whose blood samples were used to obtain the standard
values of markers in the study population. This group includes an
approximately equal number of men and women with median age
of 40, and more than half of the individuals had latent TB
infection diagnosed by the IGRA method (Table 1). The active-
disease group members were 46 patients with smear-positive active
pulmonary TB. The majority of the patients were male with low
body mass index (BMI,18.5 kg/m
2) and the median age was 47,
slightly older than in the non-symptom group.
Correlation of adiponectin, leptin, fetuin-A and RBP4
levels with BMI, CRP and IGRA values in the no-symptom
and active-disease groups
Correlation coefficients (r) were calculated in the no-symptom
and active-disease groups respectively (Table 2). Adiponectin and
leptin showed negative and positive correlations with BMI
respectively in the no-symptom group (r=20.4530, P,0.0001;
r=0.4518, P,0.0001). Leptin/adiponectin ratio showed a positive
correlation with BMI in the active-disease group (r=0.4901,
P=0.0005) as well as in the no-symptom group (r=0.5820,
P,0.0001). These correlations were statistically significant even
after Bonferroni correction for multiple comparisons. The other
possible correlations including a pair of leptin and TB-antigen
stimulated IFN-c response did not reach significant levels in this
study, when Bonferroni correction was applied.
Pairwise correlations between four tested markers
Pairwise correlation coefficients (r) between four tested meta-
bolic markers were further calculated in the no-symptom and
active-disease groups respectively (Table S1). A significant
correlation was found only between fetuin-A and RBP4 levels
(r=0.4007, P=0.0058) in the active disease group.
Adiponectin, leptin, fetuin-A and RBP4 levels with IGRA-
positive and -negative subgroups in the no-symptom
group
IGRA-positive values higher than the cutoff value, 0.35 IU/ml
are regarded as latent TB infection after active disease is ruled out.
We thus categorized the no-symptom group into IGRA-positive
and -negative subgroups and compared plasma concentrations of
the above markers. However, none of the marker levels including
fetuin-A were significantly different between IGRA-positive and -
negative subgroups after adjustment for gender and age, when
considering the number of comparisons (Table 3).
Adiponectin, leptin, fetuin-A and RBP4 levels in the no-
symptom and active-disease groups
The active-disease group had significantly low BMI and very
high CRP levels at the time of diagnosis, when assessed by using
ANCOVA with adjusted means (Table 4). In the disease group,
leptin, leptin/adiponectin ratio, fetuin-A and RBP4 levels were
remarkably lower than in the no-symptom group (P,0.0001
respectively) after adjustment for gender and age and these
differences were statistically significant even after Bonferroni
correction (Table 4).
Since BMI was strongly correlated with some of the adipokine
values as shown in Table 2, we further analyzed levels of the four
markers after adjustment for BMI as well as gender and age.
Consequently, adiponectin and leptin levels were not significantly
different between the two groups any more, whereas fetuin-A and
RBP4 levels remained significant (P=0.0004 and P=0.0001)
(Table 5)
Adiponectin, leptin, fetuin-A and RBP4 levels in patients
with mild and severe disease
At the time of diagnosis, severity of the disease was assessed by
spread of infiltrates on chest radiographs (Table 6). Small
infiltrates affecting less than 3 of the 6 lung zones and large ones
affecting more, categorized the patients into two subgroups
(=mild and severe disease) half-and-half.
After adjustment for gender and age, adiponectin levels were
higher and leptin levels were lower in patients with large infiltrates
than in those with small infiltrates (P=0.0033 and P=0.0020).
Interestingly, differences in the levels of these two adipokines
between small and large infiltrates were significant respectively
(P=0.0061 and P=0.0040), even after adjustment for BMI as well
as gender and age (Table 7). Leptin/adiponectin ratio was lower,
or adiponectin/leptin ratio was higher, in patients with large
infiltrates than in those with small infiltrates independent of BMI
(P=0.0002). None of the markers were associated with the
presence of cavity on the chest radiographs (data not shown).
Adiponectin, leptin, fetuin-A and RBP4 levels in patients
with active TB before, during and at the end of anti-TB
treatment
Figure 1 shows plasma values at the time points before (0
month), during (2 months) and at the end (7 months) of anti-TB
treatment. Mean values in men (N=41) and women (N=43) of
the no-symptom group are shown as a reference, in which gender
difference was observed in leptin levels and leptin/adiponectin
ratio (P,0.0001).
Overall differences of the measurements during anti-TB
treatment in all of these four markers were statistically significant
by repeated-measures ANOVA (P,0.01). Post-hoc analysis
showed that adiponectin levels increased transiently (P=0.0004;
0 month vs. 2 months) and then decreased close to the reference
range by the end of treatment (P,0.0001; 2 months vs. 7 months).
Leptin levels remained low throughout the treatment course,
though gradually elevated (P=0.0226; 0 month vs. 2 months).
Initial low levels of fetuin-A and RBP4 significantly improved
during treatment (P=0.0001 and P=0.0016; 0 month vs. 2
months), almost reaching the reference range by the end in concert
with reduced CRP levels.
Discussion
We assessed the clinical significance of four metabolic markers,
adiponectin, leptin, fetuin-A and RBP4 in patients with active TB,
analyzing them in relation to classical nutritional and inflamma-
tory parameters, BMI and CRP, severity of disease and treatment
course. BMI is known to be lower in patients with active TB than
in control subjects [1,2]. After effective treatment, weight often
increases but patients may remain underweight [11].
Plasma levels of adiponectin were inversely correlated with BMI
in concordance with previous results [11,12]. The adiponectin
levels tended to be elevated in the active-disease group character-
ized by low BMI, though it did not reach significant levels, which
was also shown by others [29]. Interestingly in our study,
adiponectin levels were significantly higher in severe disease with
extensive pulmonary lesions than in mild disease, even after
adjustment for BMI. Adiponectin as a modulator of inflammation
in a variety of diseases has recently been highlighted [30]. For
instance, in critically ill patients, adiponectin levels appear to be
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elevated at the recovery phase [31,32]. The plasma concentrations
in patients with active TB were further increased after starting
treatment and then decreased close to the reference range by the
end of treatment. Elevated adiponectin levels in chronic in-
flammatory diseases may be explained by compensatory response
to the underlying disease as well as concomitant low body fat mass,
which is postulated by others [33,34]. A study designed to measure
alteration of adiponectin and BMI simultaneously throughout the
treatment period would be able to characterize it further.
In most recent reports, leptin levels are low in TB [29,35–38],
though other earlier or smaller studies have shown conflicting
results [39–42]. In the present study, using a commercial ELISA,
significantly lower levels of leptin were demonstrated in patients
with active TB, which could be mostly explained by marked
undernutrition in our disease population. Within the active-disease
group, however, correlation between leptin and BMI was less
clear. BMI-independent regulation of plasma leptin concentrations
should also be taken into consideration in TB at least in part
[13,37]. This idea is also supported by an ex vivo study by others
demonstrating that continuous exposure of IL-1 or TNF-a provides
a signal to downregulate leptin in human adipose tissue [43],
though acute inflammation such as sepsis may rather upregulate
circulating leptin levels transiently [44–46]. In addition to
relatively high levels of adiponectin, low levels of leptin were
observed in patients with large infiltrates, even after adjustment for
BMI. This is concordant with a recent study showing that leptin
levels were low in severe TB disease [29]. We have further
demonstrated that low leptin/adiponectin ratio, or high adipo-
nectin/leptin ratio is characteristic to severe TB disease in this
study. This ratio was originally proposed as an atherogenic index
indicating a balance between the two markers bearing apparently
opposite functions in inflammation [47]. Our findings support the
idea that suppressed production of leptin may be detrimental to
host defense against TB by virtue of impairment of Th1 cell-
mediated immunity [13,29,48]. After starting treatment, leptin
levels were slightly elevated, but remained low during the
treatment period. This is also compatible with reports made by
others [37,38], although the mechanism remains unknown. Long-
lasting low levels of leptin may be attributed to individual
predisposition to TB or delayed recovery from wasting disease.
In our study, fetuin-A levels were considerably low in TB even
after adjustment for BMI. Soon after starting treatment, the levels
were increased in inverse proportion to the decrease in CRP. In
TB, fetuin-A may be downregulated by at least dual mechanisms,
strongly mediated by underlying inflammation [21] and partly
controlled by depleted liver fat due to wasting or malnutrition
[18]. Low fetuin-A levels may also result in impairment of
macrophage function to kill the pathogen and ectopic calcification
possibly in TB lesions [49,50].
RBP4 levels were also low in TB even after adjustment for BMI.
Throughout the treatment course, the levels were gradually
elevated close to the reference range inversely with the decrease in
CRP. These findings are supported by a recent report demon-
strating that RBP4 rapidly decreases during acute inflammation,
possibly acting as a negative acute phase reactant, similar to fetuin-
A, albumin and prealbumin [21,51,52]. This may partly explain
a close positive correlation with fetuin-A demonstrated in the
active-disease group. In addition to dual regulation of RBP4 by
underlying inflammation and low body fat mass, reduced renal
function is also known to cause retention of the circulating levels,
such that further caution is needed to interpret RBP4 measure-
ment in disease state [53].
Our study has several limitations. Firstly, many types of
nutrients including micronutrients are essential to the human
body but the potential interplay between each component of
nutrients was not within our scope at that time. Secondly, since
change of BMI was not measured during treatment, direct
comparison of improved BMI with the corresponding marker
levels was not possible. Thirdly, blood was collected during the
daytime without enforced fasting. Although, of course, this
increases the variance of measurements, it can be inferred that
daytime variations on circulating adipokines and leptin [54] are
not as large as to seriously affect conclusive results of comparisons
within and between groups in this study. Finally, computer
tomography, which has advantages over chest radiography as an
imaging tool, was not available in our setting.
Overall, our data and recent literature would suggest that all of
the four markers tested are controlled partly by low fat store and
partly by inflammation in TB but their regulatory mechanisms are
more or less different and interactions with other relevant factors
including insulin sensitivity and cellular immunity are worth
further investigation. In particular, leptin, adiponectin and their
ratio may be promising markers for severity of the wasting disease.
Since nutritional intervention has a potential to improve prognosis
of intractable TB such as HIV co-infection and MDR-TB, large-
scale prospective studies using selected biomarkers to investigate
metabolic contributors to disease phenotype are desired. The more
fully we understand the mechanisms linking diet, health, and
disease, the more effective will be our ability to design optimal
interventions.
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